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and Big ET-1 levels, and tissue expression of ET-1 in patients with
ductal carcinoma of the breast. Methods: Peripheral venous blood
samples were collected prior to diagnostic biopsy from women with
suspicious non-palpable mammographic lesions. Plasma ET-1 and Big
ET-1 levels were determined in 30 patients with IDC, 30 with DCIS and
30 with benign lesions (controls), by performing ELISA. ET-1 and VEGF
tissue expression was immunohistochemically determined. Potential
correlationswith histological grade, hormone receptor status, Her2/neu
ampliﬁcation, tumor size, lymph node involvement and disease stage
were investigated in IDC. Results: Big ET-1 plasma levels were signif-
icantly higher in IDC and DCIS patients compared to controls (p b 0.001
and p b 0.01, respectively). No signiﬁcant differences in ET-1 levels
were observed between the three groups. Moderate to strong IHC
staining for ET-1 was observed in 3/29 and 7/23 IDC and DCIS patients,
respectively. VEGF was signiﬁcantly expressed in 8/27 and 8/23 IDC
and DCIS patients, respectively. In IDC, plasma and tissue expression
of ET-1 and plasma expression of Big ET-1 did not correlate with any of
the analyzed clinicopathological characteristics or VEGF tissue expres-
sion. Conclusions: Plasma levels of Big ET-1 were a more sensitive
indicator of ET-1 deregulation than those of ET-1 in our study. Our
results support the potential clinical application of Big ET-1 as a breast
cancer biomarker.
doi:10.1016/j.lfs.2013.12.047
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Background: Endothelin-1 (ET-1) acts via two G-protein-coupled
receptors, ETA and ETB. Overexpressed ET-1 and ETA in colorectal
cancer (CRC) promote tumour growth and progression. Aim: To
investigate (1) ETA and ETB distribution in normal and cancer tissues
from patients with CRC and (2) determine ETA and ETB localisation to
cell types and tissue structures. Methods: ETA and ETB distribution was
determined using in vitro autoradiographywith competitive inhibition,
using receptor antagonists (BQ123, ZD4054, BQ788) on normal and
cancer tissues resected from patients with CRC (N= 8). Immunohis-
tochemistry (IHC) conﬁrmed ETA and ETB expression and identiﬁed
associated cells/structures. ETA distribution was also investigated by
quantum dots (QDs) conjugated to BQ123 (ETA-antagonist). Results: In
normal bowel epithelium, ETA was observed closer to the luminal
surface and ETB towards the muscularis mucosa/lamina propria. There
was greater ETA than ETB binding in CRC. Both cancer and normal
tissues demonstrated strongest binding to stromal cells, particularly
ﬁbroblasts (IHC). QD-BQ123 demonstrated an ETA punctate pattern in
stromal areas surrounding epithelial cells; and an ETA increase in CRC
compared to normal. Conclusions: ET-1 binds strongly to CRC stromal
structures, with ETA greater than ETB, and is consistent with ET-1
signalling contributing to tumourigenesis. Within normal tissue, dif-
ferential ETA and ETB distribution (luminal versus muscularis mucosa/
lamina propria) has not been reported previously. This may relate to
trophic, growth arrest and differentiation signalling. This study dem-
onstrates the effective, novel use of receptor-antagonist-conjugated
QDs; reveals possible ET-1 roles in normal tissue; and provides further
evidence for the potential therapeutic use of ETA antagonists as CRC
adjuvant treatment.
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Background: The endothelin A receptor (ETA)mediates tumourigenic
signals in colorectal cancer (CRC). The ETA ligand, endothelin-1 (ET-1),
stimulates not only cancer cells but also surrounding ﬁbroblasts andmay
promote the creation of a supporting tumour stroma. Aim: To identify
ET-1 regulated genes associated with oncogenic pathways in colonic
ﬁbroblasts. Methods:Micro-array analysis following 4 h ET-1 stimulation
of colonic ﬁbroblast strains (isolated from patients undergoing resection
for CRC, n = 4) identiﬁed differentially expressed genes (n= 19) at
signiﬁcant levels. Three were investigated further: COLXI, AML-1, and
EGFR (collagen type-XI; acute myeloid leukemia-1; epidermal growth-
factor receptor). Quantitative RT-PCR (qRT-PCR) and immunoblotting
evaluated AML-1 and COLX expression levels, following treatment with
ET-1 and/or receptor antagonists (ETA: BQ123, ZD4054; ETB: BQ788).
ETA and ETB regulation of EGFR was investigated by gene silencing
(siRNA); these assays and ET-1 regulation of EGFR over 24 h were
evaluated by qRT-PCR. Results: ET-1 stimulated expression of AML-1 and
COLXI at both gene (N1.5-fold; p b 0.01) and protein (p b 0.05) levels;
stimulation was inhibited by ETA, but not by ETB, antagonism (AML-1:
75.1–77.1% by BQ123, ZD4054; COLXI: 65.1% by ZD4054; p b 0.05). EGFR
expression demonstrated a biphasic increase at 4 h and 24 h (3.8-fold;
4.5-fold). Silencing ETA, but not ETB, returned EGFR levels to control.
Conclusions: ETA antagonism has potential for targeting oncogenic
pathways: AML-1 is linked to c-Jun N-terminal kinase which inhibits
apoptosis/promotes proliferation; and abnormal TGF-β (transforming
growth-factor-beta) signalling. COLXI is linked to CRC tumourogenesis.
The ET-1-stimulated biphasic EGFR response and ETA antagonism have
not been reported before in CRC. These ﬁndings identify mechanisms
by which ETA promotes tumourigenesis and support addition of ZD4054
to existing EGFR antagonism therapy.
doi:10.1016/j.lfs.2013.12.049
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